Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595,…
Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595,…
Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595,…
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a…
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a…
$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to…
$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to…
Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure…
Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure…
Tigris Trial Enrollment Reaches 71 Patients TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Spectral Medical…
Tigris Trial Enrollment Reaches 71 Patients TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Spectral Medical…
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage…
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage…
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with…
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with…
Alimera Acquired U.S. Commercial Rights to YUTIQ® Landmark NEW DAY Study Completed Enrollment with over…
Alimera Acquired U.S. Commercial Rights to YUTIQ® Landmark NEW DAY Study Completed Enrollment with over…
DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the…
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the…